Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
复制标题
DOI：
10.1111/j.1463-1326.2011.01380.x
复制
发表时间：
2011-07-01
影响因子：
5.8
通讯作者：
Giugliano, D.
中科院分区：
文献类型：
--
作者：
Esposito, K.;Cozzolino, D.;Giugliano, D.
目的：我们评估了二肽基肽酶-4（DPP-4）抑制剂维达利、西格列汀、沙格列汀和阿格列汀对2型糖尿病患者达到HbA 1c < 7%目标的疗效。方法：我们对2010年9月之前涉及DPP-4抑制剂的随机对照试验（RCT）进行了电子检索。如果RCT持续至少12周，纳入30例或更多患者，并报告达到HbA 1c目标的患者比例，则纳入RCT
Aim: We assessed the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin, sitagliptin, saxagliptin and alogliptin to reach the haemoglobin HbA1c target of < 7% in people with type 2 diabetes.Methods: We conducted an electronic search for randomized controlled trials (RCTs) involving DPP-4 inhibitors through September 2010. RCTs were included if they lasted at least 12 weeks, included 30 patients or more and reported the proportion of patients reaching the HbA1c target of